Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Other Accumulated Expenses (2017 - 2025)

VYNE Therapeutics' Other Accumulated Expenses history spans 7 years, with the latest figure at $1.3 million for Q1 2025.

  • For Q1 2025, Other Accumulated Expenses changed N/A year-over-year to $1.3 million; the TTM value through Mar 2025 reached $1.3 million, changed N/A, while the annual FY2024 figure was $1.3 million, N/A changed from the prior year.
  • Other Accumulated Expenses reached $1.3 million in Q1 2025 per VYNE's latest filing, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q2 2024 to a low of $104000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 3 years is $794857.1, with a median of $1.3 million recorded in 2024.
  • The largest YoY upside for Other Accumulated Expenses was 126.09% in 2021 against a maximum downside of 72.77% in 2021.
  • A 3-year view of Other Accumulated Expenses shows it stood at $104000.0 in 2021, then surged by 1162.5% to $1.3 million in 2024, then changed by 0.0% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Other Accumulated Expenses are $1.3 million (Q1 2025), $1.3 million (Q4 2024), and $1.3 million (Q3 2024).